** Medtech stocks are set to end 2025 on a mixed note, with shares of Becton Dickinson BDX.N, Zimmer Biomet ZBH.N, Baxter BAX.N and Stryker SYK.N headed for yearly losses

** Boston Scientific BSX.N, Medtronic MDT.N, Johnson & Johnson JNJ.N, Abbott ABT.N, Edwards Lifesciences EW.N and GE HealthCare GEHC.O, however, are on track to finish the year in positive territory

** Zimmer Biomet shares are down 14.1% this year amid repeated profit warnings and are bracing for a third consecutive loss, while Baxter has shed about 33.8% in 2025 and faces a fourth straight year in the red due to continued pain from profit warnings and hurricane disruptions at its key facility

** Edwards Lifesciences, Boston Scientific, and Abbott shares are set to end 2025 up over 16%, 7%, and 11%, respectively. BSX and EW posted standout gains on repeated profit upgrades and strong revenue from top heart devices

** JNJ investors rewarded consistent beats, with the stock climbing over 43%, hitting a record high, outpacing the medtech sector and snapping a two-year losing streak

** "We see hope for a more peaceful '26 for MedTech. With tariffs mitigated and policy risks manageable, we expect robust MedTech growth and remain constructive," said Jefferies analysts in a note two weeks ago

(Reporting by Padmanabhan Ananthan)

((Padmanabhan.Ananthan@thomsonreuters.com))